Biobanking Working Group Update

NMD4C is committed to strengthening the biobanking resources available to Canadian neuromuscular researchers. In rare diseases, the availability of biosamples is often limited, which hinders research into disease pathogenesis and mechanisms, and therapy development.

NMD4C is pleased to announce the addition of network collaborator Dr. Jason Karamchandani to the biobanking working group. Dr. Karamchandani is an Associate Professor in the Department of Pathology and a neuropathologist at the Montreal Neurological Institute and Hospital, who brings biobanking experience from his work with the Clinical Biospecimen Imaging and Genetic Repository (C-BIG). Dr. Karamchandani will lead the NMD4C in creating a virtual Canadian biobank, a central catalogue which will contain the neuromuscular samples available for research at the different biobanking sites across Canada.

The NMD4C biobanking group has identified eight biobanks (BDMB-MNM-MA, C-BIG, CHU Dumont Biobank, CIMS, CREATION, Neurobiobank, Pfeffer Lab Biobank) that collect and prepare a variety of samples covering a range of neuromuscular diseases. Each of these sites has provided information about what they collect, and the conditions and policies for researchers to access them. While the virtual biobank catalogue is under development, we have listed the biobanks with a summary of the NMDs covered, samples collected, associated sample data, material transfer agreements in place, context of how samples are used, and contact information on the NMD4C site, which you can access here.

If you know of any biobanks that we have missed or are involved in sample collection yourself and are interested in being listed on the NMD4C site and contributing to the virtual biobank catalogue, please let us know!

Logo_Biobank map

Read next...

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.

Website - SBMA published on CMAJ.png

New Best Practice Recommendations for SBMA Care in Canada

Congratulations to Dr. Kerri Schellenberg, the team of Canadian experts, NMD4C Steering Committee members and Investigators, on publishing the first Canadian SBMA care guidelines!

2025 NMD4C ANNUAL MEETING

Advancing Neuromuscular Research and Care: Highlights from the 2025 NMD4C Annual Meeting

On September 11, NMD4C hosted its 2025 Annual Meeting in Ottawa, bringing together clinicians, researchers, trainees, and partners for a full day of collaboration, strategic dialogue, and community-building.

2025 Clinical Summer School

NMD4C Hosts Inaugural Clinical Summer School to Empower Canada’s Future Neuromuscular Leaders

On September 10–11, NMD4C hosted its inaugural Clinical Summer School in Ottawa, bringing together 19 neuromuscular clinical fellows from across Canada for two days of hands-on training, mentorship, and networking. Led by national experts and co-chaired by Drs. Gordon Jewitt and Marianne Nury, the program complemented NMD4C’s accredited lecture series and fostered peer connection through dedicated community-building sessions.

2026 Neuromuscular Postdoc Research Fellowship Competition

2026 Neuromuscular Postdoctoral Research Fellowships Funding Competition is Now Open!

Apply Or Share this opportunity with the trainees in your network — Deadline: October 14, 2025. Hosted by Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC)

Clinical Fellowship Awardees

Announcing the 2026 Neuromuscular Clinical Fellowship Award Recipients

We are excited to share that the 2026 Neuromuscular Clinical Fellowship Awards have been awarded! These fellowships strengthen clinical training in neuromuscular medicine and help prepare the next generation of specialists who will advance neuromuscular care across Canada.